Thursday Dec 5
Drugs with dual-hormone action gain attention in diabetes field
Engineered peptide drugs that simultaneously target two hormone receptors have historically attracted interest among scientists hoping to create new treatments for diabetes.
Research and Markets: Amylin Pharmaceuticals and Eli Lilly's Bydureon ...
Research and Markets: Amylin Pharmaceuticals and Eli Lilly's Bydureon Type 2 Diabetes - Forecast and Market Analysis to 2022 The type 2 diabetes market is mature and crowded with inexpensive generics.
Market Report, "Amylin Pharmaceuticals, Inc. - Pharmaceuticals &...
Amylin Pharmaceuticals, Inc. , subsidiary of Bristol-Myers Squibb, is a biopharmaceutical company.
Profil Institute Appoints Dan Bradbury, former Amylin Pharmaceutical CEO, to Board of Directors
Profil Institute for Clinical Research, Inc., a company providing science-driven early phase diabetes and obesity clinical research, announced today the appointment of Dan Bradbury, Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO, to its Board of Directors.
A.P. Pharma Makes Management Appointments
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced the appointment of Paul Marshall as senior vice president of technical operations and Brian Drazba as vice president of finance and chief financial officer.